United Capital Financial Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.08M Sell
101,985
-222
-0.2% -$17.9K 0.05% 271
2025
Q4
$8.4M Buy
102,207
+17,112
+20% +$1.32M 0.05% 274
2025
Q3
$5.95M Buy
+85,095
New +$5.75M 0.04% 274
2022
Q1
Sell
-2,962
Closed -$211K 1203
2021
Q4
$211K Hold
2,962
﹤0.01% 1138
2021
Q3
$222K Hold
2,962
﹤0.01% 1106
2021
Q2
$229K Hold
2,962
﹤0.01% 1120
2021
Q1
$219K Hold
2,962
﹤0.01% 1089
2020
Q4
$208K Buy
+2,962
New +$188K ﹤0.01% 1118
2020
Q3
Sell
-4,462
Closed -$260K 1213
2020
Q2
$260K Hold
4,462
﹤0.01% 1028
2020
Q1
$207K Sell
4,462
-612
-12% -$31.9K ﹤0.01% 1063
2019
Q4
$283K Buy
5,074
+277
+6% +$14.4K ﹤0.01% 1160
2019
Q3
$227K Buy
4,797
+271
+6% +$13.9K ﹤0.01% 1155
2019
Q2
$242K Hold
4,526
﹤0.01% 1298
2019
Q1
$250K Sell
4,526
-100
-2% -$5.29K ﹤0.01% 1197
2018
Q4
$218K Buy
4,626
+100
+2% +$5.14K ﹤0.01% 1171
2018
Q3
$269K Sell
4,526
-275
-6% -$16K ﹤0.01% 1153
2018
Q2
$263K Buy
4,801
+275
+6% +$14K ﹤0.01% 1133
2018
Q1
$223K Hold
4,526
﹤0.01% 1204
2017
Q4
$213K Buy
+4,526
New +$212K ﹤0.01% 1222

Other funds holding PBE

United Capital Financial Advisors's PBE Position: Q1 2026 in Review

United Capital Financial Advisors reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 0.22% in Q1 2026, selling an estimated $17.9K and leaving 101,985 shares worth $8.08M. The position accounts for 0.05% of the portfolio, ranked #271.

United Capital Financial Advisors first reported a position in PBE in Q4 2017 and has held it in 19 quarters since. The position peaked at $8.4M in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • United Capital Financial Advisors held 101,985 shares of Invesco Biotechnology & Genome ETF worth $8.08M as of Q1 2026.
  • United Capital Financial Advisors sold 222 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $17.9K.
  • Invesco Biotechnology & Genome ETF made up 0.05% of United Capital Financial Advisors's portfolio in Q1 2026, its #271 holding.
  • United Capital Financial Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2017 and has held it in 19 quarters since.
  • United Capital Financial Advisors's Invesco Biotechnology & Genome ETF position peaked at $8.4M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on United Capital Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.